← All indications
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (19)
Phase 2 trials (113)
- metformin
- s-methionine
- ly-3023414
- abemaciclib
- acellular dermal matrix
- dexrazoxane
- anlotinib
- allogeneic natural killer cells
- plerixafor
- olaparib
- sorafenib
- bio-11006
- talazoparib
- bvd-523
- temsirolimus
- cd40 ligand
- cixutumumab
- silmitasertib
- eflornithine
- e7 peptide
- eribulin
- ef-1 peptide
- ef-2 peptide
- erdafitinib
- fulvestrant
- figitumumab
- fluzoparib
- vismodegib
- gemcitabine
- tacrolimus
- +83 more
Phase 1 trials (39)
- simvastatin
- fluorothymidine
- thalidomide
- autologous tumor infiltrating lymphocytes
- Iopofosine
- selinexor
- enoblituzumab
- incb059872
- ixazomib
- lexatumumab
- dinutuximab
- niraparib
- allogeneic stem cells
- hsv-1716
- pbi-shrna ews/fli1 type 1 lpx
- pexastimogene devacirepvec
- racotumomab
- romiplostim
- stem cells
- tanespimycin
- alemtuzumab
- vorinostat
- tumor-pulsed dendritic cells
- interferon gamma-1b
- tp-1287
- nogapendekin alfa inbakicept
- alvocidib
- inbrx-109
- b7-h3 car-t
- lifileucel
- +9 more
Organizations
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (85)
- Daiichi Sankyo
- Eisai
- Celgene
- Bristol-Myers Squibb
- Amgen
- Astellas
- Imclone
- Eli Lilly
- Genentech
- Genzyme
- Pfizer
- Sanofi
- BioInvent International AB
- NantCell, Inc.
- Oncurious NV
- Oncolytics Biotech
- Sarcoma Oncology Research Center, LLC
- Tyme, Inc
- Aadi, LLC
- PharmaMar
- National Institutes of Health (NIH)
- University of Arizona
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Cornell University
- Harvard University
- Florida International University
- University of Washington
- Grupo Espanol de Investigacion en Sarcomas
- +55 more
Organization Involved with Phase 1 Indications (36)
- Incyte
- Takeda
- Merckle
- Medivation
- Karyopharm Therapeutics Inc
- Laboratorio Elea S.A.C.I.F. y A.
- MacroGenics
- Teva
- Strike Bio, Inc.
- University of Pittsburgh
- Baylor University
- Case Western Reserve University
- Duke University
- Emory University
- New York Medical College
- Ohio State University
- University of Louisville
- Columbia University
- South Plains Oncology Consortium
- University of Buenos Aires
- University of Cincinnati
- Oncternal Therapeutics
- Sumitomo Dainippon
- Janssen Pharmaceutica NV
- Cellectar, Inc
- Mary Crowley Cancer Center
- University of Wisconsin
- Jennerex Inc.
- University of Alabama, Birmingham
- University of Tuebingen
- +6 more
Organization Involved with Other Experimental Indications (7)